This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2017 Nov 15:247:8.

doi: 10.1016/j.ijcard.2017.07.075.

Reply to: Cardiovascular safety of canagliflozin

No authors listed

PMID: 28916093
DOI: 10.1016/j.ijcard.2017.07.075

Comment

Reply to: Cardiovascular safety of canagliflozin

No authors listed. Int J Cardiol. 2017.

. 2017 Nov 15:247:8.

doi: 10.1016/j.ijcard.2017.07.075.

PMID: 28916093
DOI: 10.1016/j.ijcard.2017.07.075

No abstract available

PubMed Disclaimer

Comment on

Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
Ghosh RK, Bandyopadhyay D, Hajra A, Biswas M, Gupta A. Ghosh RK, et al. Int J Cardiol. 2016 Jun 1;212:29-36. doi: 10.1016/j.ijcard.2016.02.134. Epub 2016 Mar 10. Int J Cardiol. 2016. PMID: 27017118 Review.
Cardiovascular safety of canagliflozin.
Qureshi A, Bandyopadhyay D, Hajra A. Qureshi A, et al. Int J Cardiol. 2017 Nov 15;247:7. doi: 10.1016/j.ijcard.2017.06.128. Int J Cardiol. 2017. PMID: 28916092 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations